Socio-territorial movements, women and food donation in Brazil: solidarity campaigns as resistance during the COVID-19 pandemic. (Estudos agrarios criticos e COVID-19: movimentos socioterritoriais e luta pela terra no Brasil.)

In Brazil, during the COViD-19 pandemic, the deepening of the issue of serious food insecurity and violence against women became one of the main impacts enhanced by the stance adopted by the government of Jair Messias Bolsonaro. In view of this, different subjects, organized into socio-territorial movements in the countryside and in the city, carried out resistance actions to mitigate these problems, with solidarity as a nucleating element. This work analyzes the actions of peasant women in food donation campaigns based on the paradigmatic debate, through bibliographic surveys, systematization of quantitative data and interviews. Women are at the center of actions aimed at the campaigns, characterized by the diversity of identities of the participating subjects, with donations of lunch-boxes, baskets, hygiene/cleaning products, etc. Such actions are based on the Paradigm of the Agrarian Question, as they seek to overcome the structural problems of capital and propose socio-territorial changes for a new model of society, based on social justice and the promotion of popular agrarian reform.

Correlations between web searches and COVID-19 epidemiological indicators in Brazil

COVID-19 rapidly spread across the world in an unprecedented outbreak with a massive number of infected and fatalities. The pandemic was heavily discussed and searched on the internet, which generated big amounts of data related to it. This led to the possibility of attempting to forecast coronavirus indicators using the internet data. For this study, Google Trends statistics for 124 selected search terms related to pandemic were used in an attempt to find which keywords had the best Spearman correlations with a lag, as well as a forecasting model. It was found that keywords related to coronavirus testing among some others, such as "I have contracted covid", had high correlations (0.7) with few weeks of lag (4 weeks). Besides that, the ARIMAX model using those keywords had promising results in predicting the increase or decrease of epidemiological indicators, although it was not able to predict their exact values. Thus, we found that Google Trends data may be useful for predicting outbreaks of coronavirus a few weeks before they happen, and may be used as an auxiliary tool in monitoring and forecasting the disease in Brazil.

ANÁLISE DOS TRANSPLANTES DE MEDULA ÓSSEA REALIZADOS NO BRASIL ENTRE 2015 E 2020

Introdução: O transplante de medula óssea (TMO) é um método de tratamento para algumas doenças que afetam as células sanguíneas, como anemias, mielodisplasias e leucemias. O procedimento objetiva reconstruir a medula doente ou deficitária através de células saudáveis. O TMO pode ser autogênico, medula do próprio paciente;alogênico, medula de um doador, ou ainda feito a partir de células precursoras de medula óssea, obtidas do sangue circulante de um doador ou do sangue de cordão umbilical. O Brasil possui um dos maiores bancos de doadores de medula óssea do mundo, todavia sabe-se que as chances de encontrar uma medula óssea que seja compatível é muito rara. Objetivos: O objetivo do artigo é analisar o número de transplantes de medula óssea (TMO), na população geral, realizados no Brasil entre os anos de 2015 a 2020. Metodologia: Estudo transversal descritivo que traz o número de transplantes de medula óssea, autólogos e alogênicos, realizados no Brasil, entre os anos de 2015 a 2020, por meio dos dados apontados nos boletins anuais de Registro Brasileiro de Transplantes (RBT). Resultados: Entre os anos de 2015 a 2020, foram realizados um total de 17.210 transplantes de medula óssea no Brasil, de forma que 6.657 são alogênicos e 10.553 autólogos. A média anual de transplantes foi de aproximadamente 2.868 com desvio padrão (DP) 637,43. Os alogênicos apresentaram uma média anual de 1.109 e os autólogos de 1.758, aproximadamente. No período entre 2015-2019 houve um crescimento médio anual de 15,8% e um crescimento total de aproximadamente 44% de procedimentos realizados. Entretanto, no período entre 2019-2020 houve uma redução de 16% dos procedimentos. Discussão: Diante dos resultados obtidos, constata-se que houve um aumento significativo no número de procedimentos realizados a respeito dos transplantes de medula óssea entre 2015 e 2020. Assim, destes, os transplantes do tipo autólogos tiveram maior destaque. Assim, o crescimento médio e total entre esses anos tem mais evidência de aumento, se comparado aos anos de 2019 e 2020, em que o número de procedimentos diminuiu. Conclusão: Portanto, o aumento do número de transplantes no período de 2015 a 2019 decorre do aumento da expectativa de vida e da evolução em tecnologia e no sistema de saúde. Inclusive nosso sistema nacional de transplantes é referência para o mundo. Ademais, justifica-se a queda no número de procedimentos entre 2019 e 2020 devido a pandemia da Sars-Cov-2.

P0124 The impact Of COVID-19 on acute obstructive pyelonephritis severity - 2020 and its unforeseen presentations

INTRODUCTION & Objectives: The World Health Organisation (WHO) announced the coronavirus disease-19 (COVID-19) a pandemic on 12th March 2020. The subsequent diversion of healthcare and public attention towards virus exposure avoidance resulted in an alarming change in emergency department (ED) presentations for many serious medical conditions, namely acute obstructive pyelonephritis (AOP). We sought to assess the impact inflicted by the COVID-19 pandemic on the presentation severity of patients diagnosed with AOP who attended the ED before and after the disease was declared a pandemic. Materials & Methods: We conducted an observational retrospective study analysing data from patients submitted to a temporary urinary diversion with a ureteral double J stent (JJ) from January 2017 to December2020, in a tertiary care centre. Patient cohorts before and after 12th March 2020 were compared. We included patients admitted to the EDwho underwent ureteral stenting in the setting of AOP. We excluded patients submitted to percutaneous urinary diversion and those who underwent JJ placement due to indications other than AOP. Patients' demographics, comorbidities (Charlson Comorbidity Index - CCI), vital signs, chemistry and imaging results at ED admission and during ED stay were analysed. Sequential OrganFailure Assessment (SOFA) score at admission was obtained and the need foradmission in an Intensive Care Unit (ICU)was recorded. The duration of the hospital stay was evaluated. Results: A total of 130 patients were analysed, 97 of those weresubmitted to JJ placement before the COVID-19 outbreak and 33 after. The mean number of patients monthly undergoing a JJ placement raised from 2 to 4 before and after March 2020, respectively. They had comparable age (58±18 vs. 59±18 years old) and comorbidities (as depicted by the CCI) as well as stone location (p=0.292), laterality (p=0.419) and dimension (8mm, p=0.715). Computed Tomography (CT) had a significantly higher use as imaging modality in the ED during the post-COVID-19 era (5.2% vs. 33.3%, p<0.001). There was a non-statistically significant tendency towards a longer time to ED visit in the post-COVID-19 cohort (48 vs. 72 hours,p=0.052). The severity at ED presentation, as evaluated by SOFA score, was identical (p=0.160). Nevertheless, a greater number of patients presented to the ED with sepsis criteria (21.6% vs. 36.4%, p=0.093) and a significantly higher number of patients were admitted to an ICU in the post-COVID-19 period (1% vs. 15.2%, p=0.004) spending 7 days there (on average). Conclusions: The COVID-19 pandemic determined an increase in the number of patients admitted to the ED due to AOP and a higher rate of ICU admission. These findings may be related to the deferral in stone disease elective procedures. The virus exposure avoidance might have led, concurrently, to a longer time until ED visit from the symptom onset.

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma

Background:COVID-19 adversely affects individuals with cancer. Several studies have found that seroconversion rates among patients with hematologic malignancies are suboptimal when compared to patients without cancer. Among patients with hematologic malignancies, seroconversion rates also appear to be influenced by recent treatment and the type of treatment they have received. Patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) are immunocompromised due to impaired humoral and cellular immunity in addition to prescribed immunosuppressive therapy. Chimeric antigen receptor T-cell (CAR T) therapy is now widely used for NHL and MM, but little is known about seroconversion rates after COVID-19 vaccination among these populations. Current national guidelines recommend COVID-19 vaccination to be offered to CAR T recipients as early as three months thereafter. We retrospectively evaluated SARS-CoV-2 spike-binding IgG antibody levels following COVID-19 vaccination among NHL and MM CAR T therapy recipients. Methods:This retrospective study was conducted at three Mayo Clinic sites on NHL and MM patients that received CAR T infusions from Sept 2016 to June 2021. Baseline characteristics were ascertained from medical records. All NHL and MM patients who had received CAR T at any point and were alive at the time that the COVID-19 vaccine first became available were eligible for inclusion for antibody response evaluation. For antibody response to vaccination, antibody spike values > 0.80 U/mL were considered positive. Results: Out of 104 CAR T infusions, 73 patients are alive at the time of this submission. We have had 7 patients with known COVID-19 pre-CAR T and all 7 are currently alive (5 have antibody titers and 2 have not been tested yet). Nineteen patients developed known COVID infection post-CAR T (13 alive and 6 deceased). The mortality of COVID post-CAR T in our sample was 31.5%. Furthermore, of the 13 patients that survived COVID-19, they received CAR T an average of 416 days prior to COVID-19 infection (median = 337, range = 54 - 1406);the 6 patients who died from COVID-19 had received CAR T an average of 250 days prior to COVID-19 infection (median = 164, range = 7 - 846). All 6 deceased patients did not receive COVID-19 vaccination pre-CAR T. Out of 17 CAR T patients tested for antibody spike titers post COVID-19 vaccination, 76.4% were able to mount an antibody response. More patients with MM had a higher titer response to the vaccine (>250 U/mL) compared to the NHL counterparts (0.80-249 U/mL). All patients that received the vaccine, regardless of antibody response, were alive at the time of this submission. Conclusions:The majority of CAR T recipients with NHL and MM are able to mount an antibody response following COVID-19 vaccination in our relatively small sample. The frequency of seroconversion among CAR T recipients seems to be similar to patients with hematologic malignancy who had received a hematopoietic cell transplant reported elsewhere. These findings are limited by our small sample size and may be influenced by the timing of vaccination relative to CAR T. Furthermore, almost half of our patients received IVIG post CAR T which could potentially cause false positive antibody results as pooled immunoglobulin preparations may contain COVID-19 antibodies from vaccinated healthy donors. To better understand the characteristics of the immunologic response against SARS-CoV-2 in patients post-CAR T, larger multicenter studies exploring both humoral and cellular immunity will be needed. JEWN, MI and JM are co-first authors and PV, HM and AR are co-senior authors. [Formula presented] Disclosures: Munoz: Physicians' Education Resource: Honoraria;Seattle Genetics: Honoraria;Bayer: Research Funding;Gilead/Kite Pharma: Research Funding;Celgene: Research Funding;Merck: Research Funding;Portola: Research Funding;Incyte: Research Funding;Genentech: Research Funding;Pharmacyclics: Research Funding;Seattle Genetics: Research Funding;Janssen: Research Funding;Millennium: Research Funding;Gilea /Kite Pharma, Kyowa, Bayer, Pharmacyclics/Janssen, Seattle Genetics, Acrotech/Aurobindo, Beigene, Verastem, AstraZeneca, Celgene/BMS, Genentech/Roche.: Speakers Bureau;Pharmacyclics/Abbvie, Bayer, Gilead/Kite Pharma, Pfizer, Janssen, Juno/Celgene, BMS, Kyowa, Alexion, Beigene, Fosunkite, Innovent, Seattle Genetics, Debiopharm, Karyopharm, Genmab, ADC Therapeutics, Epizyme, Beigene, Servier: Consultancy;Targeted Oncology: Honoraria;OncView: Honoraria;Kyowa: Honoraria. Bergsagel: Oncopeptides: Consultancy, Honoraria;Novartis: Consultancy, Honoraria, Patents & Royalties: human CRBN mouse;Pfizer: Consultancy, Honoraria;Celgene: Consultancy, Honoraria;Janssen: Consultancy, Honoraria;Genetech: Consultancy, Honoraria;GSK: Consultancy, Honoraria. Wang: Incyte: Membership on an entity's Board of Directors or advisory committees, Research Funding;LOXO Oncology: Membership on an entity's Board of Directors or advisory committees, Research Funding;Genentech: Research Funding;InnoCare: Research Funding;Novartis: Research Funding;MorphoSys: Research Funding;Eli Lilly: Membership on an entity's Board of Directors or advisory committees;TG Therapeutics: Membership on an entity's Board of Directors or advisory committees. Fonseca: Juno: Consultancy;Kite: Consultancy;Aduro: Consultancy;OncoTracker: Consultancy, Membership on an entity's Board of Directors or advisory committees;GSK: Consultancy;AbbVie: Consultancy;Patent: Prognosticaton of myeloma via FISH: Patents & Royalties;Caris Life Sciences: Membership on an entity's Board of Directors or advisory committees;Scientific Advisory Board: Adaptive Biotechnologies: Membership on an entity's Board of Directors or advisory committees;BMS: Consultancy;Amgen: Consultancy;Sanofi: Consultancy;Merck: Consultancy;Mayo Clinic in Arizona: Current Employment;Celgene: Consultancy;Takeda: Consultancy;Bayer: Consultancy;Janssen: Consultancy;Novartis: Consultancy;Pharmacyclics: Consultancy. Palmer: Sierra Oncology: Consultancy, Research Funding;CTI BioPharma: Consultancy, Research Funding;Protagonist: Consultancy, Research Funding;Incyte: Research Funding;PharmaEssentia: Research Funding. Dingli: Novartis: Research Funding;GSK: Consultancy;Apellis: Consultancy;Alexion: Consultancy;Sanofi: Consultancy;Janssen: Consultancy. Kapoor: Sanofi: Research Funding;AbbVie: Research Funding;Takeda: Research Funding;Karyopharm: Consultancy;Cellectar: Consultancy;BeiGene: Consultancy;Pharmacyclics: Consultancy;Sanofi: Consultancy;Amgen: Research Funding;Ichnos Sciences: Research Funding;Regeneron Pharmaceuticals: Research Funding;Glaxo SmithKline: Research Funding;Karyopharm: Research Funding. Kumar: Roche-Genentech: Consultancy, Research Funding;Oncopeptides: Consultancy;Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding;BMS: Consultancy, Research Funding;Beigene: Consultancy;Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding;Novartis: Research Funding;Adaptive: Membership on an entity's Board of Directors or advisory committees, Research Funding;Astra-Zeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding;Tenebio: Research Funding;Merck: Research Funding;Carsgen: Research Funding;KITE: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding;Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding;Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding;Amgen: Consultancy, Research Funding;Bluebird Bio: Consultancy;Antengene: Consultancy, Honoraria;Sanofi: Research Funding. Paludo: Karyopharm: Research Funding. Bennani: Kymera: Other: Advisory Board;Vividion: Other: Advisory Board;Kyowa Kirin: Other: Advisory Board;Daichii Sankyo Inc: Other: Advisory Board;Purdue Pharma: Other: Advisory Board;Verastem: Other: Advisory Board. Ansell: Bristol Myers Squibb, ADC Therapeutics, Seattle Genetics, Regeneron, Affimed, AI Therapeutics, Pfizer, Trillium and Takeda: Research Funding. Lin: Kite, a Gilead Company: Consultancy, Research Funding;Merck: Research Funding;Gamida Cell: Consultancy;Takeda: Research Funding;Juno: Consultancy;Bluebird Bio: Consultancy, Research Funding;Celgene: Consultancy, Research Funding;Novartis: Consultancy;Janssen: Consultancy, Research Funding;Sorrento: Consultancy;Legend: Consultancy;Vineti: Consultancy. Murthy: CRISPR Therapeutics: Research Funding.

Early Impact of the COVID-19 pandemic on household finances in Quebec

The coronavirus disease 2019 (COVID-19) pandemic surged in early March 2020, with unemployment reaching historic levels in April 2020. This study paints an early portrait of the pandemic's impact on the finances of households in Quebec, one of the hardest-hit provinces in terms of COVID-19 cases as well as unemployment levels. The article also provides an understanding of how government emergency benefit programs may have helped households get by during the early period of the pandemic. Finally, we draw on expectations data collected in a survey of 3,009 respondents living in Quebec to illustrate what households can expect for the rest of 2020. © 2020 University of Toronto Press Inc.. All rights reserved.